Cited by 75Heme Oxygenase-1 and Carbon MonoxideDown syndrome and intellectual disability researchAlzheimer's disease research and treatments

Bach1 Overexpression in Down Syndrome Correlates with the Alteration of the HO-1/BVR-A System: Insights for Transition to Alzheimer's Disease

Open access
Di Domenico, Fabio, Pupo, Gilda, Mancuso, Cesare, Barone, Eugenio, Paolini, Francesca, Arena, Andrea, Blarzino, Carla, Schmitt, Frederick A. +3 more·2015·Journal of Alzheimer’s Disease

Abstract

Bach1, among the genes encoded on chromosome 21, is a transcription repressor, which binds to antioxidant response elements of DNA thus inhibiting the transcription of specific genes involved in the cell stress response including heme oxygenase-1 (HO-1). HO-1 and its partner, biliverdin reductase-A (BVR-A), are upregulated in response to oxidative stress in order to protect cells against further damage. Since oxidative stress is an early event in Down syndrome (DS) and might contribute to the development of multiple deleterious DS phenotypes, including Alzheimer's disease (AD) pathology, we investigated the status of the Bach1/HO-1/BVR-A axis in DS and its possible implications for the development of AD. In the present study, we showed increased total Bach1 protein levels in the brain of all DS cases coupled with reduced induction of brain HO-1. Furthermore, increased oxidative stress could, on one hand, overcome the inhibitory effects of Bach1 and, on the other hand, promote BVR-A impairment. Our data show that the development of AD in DS subjects is characterized by (i) increased Bach1 total and poly-ubiquitination; (ii) increased HO-1 protein levels; and (iii) increased nitration of BVR-A followed by reduced activity. To corroborate our findings, we analyzed Bach1, HO-1, and BVR-A status in the Ts65Dn mouse model at 3 (young) and 15 (old) months of age. The above data support the hypothesis that the dysregulation of HO-1/BVR-A system contributes to the early increase of oxidative stress in DS and provide potential mechanistic paths involved in the neurodegenerative process and AD development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-141254

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Both a dose effect from APP triplication and gene-environment interactions likely contribute to Alzheimer-like dementia in Down syndrome.

    “It is likely that both a dose effect of triplication of APP and gene-environment interactions play a role59,60.”

    From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [60]

    The Introduction (page unavailable) identifies APP as a chromosome 21 gene and reports that amyloid accumulation in Down syndrome increases with age, leading generally to Alzheimer pathology. It also says Down syndrome phenotypes need not arise exclusively from specific chromosome 21 genes. The paper does not specifically attribute Alzheimer-like dementia to an APP triplication dose effect or to gene–environment interactions. (LLM, conf=0.76)

    Experimental — accuracy not yet measured
  • People with Down syndrome often develop Alzheimer-like dementia at approximately 40 to 50 years of age.

    “One striking characteristic of people with DS is that at approximately 40–50 years of age, AD-like dementia often appears59,60.”

    From Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease (2019) · cites this paper as [60]

    The Introduction (page unavailable) says Alzheimer disease pathology generally develops in people with Down syndrome by the fourth decade of life, and Methods > Subjects says all studied cases with both Down syndrome and neuropathological Alzheimer disease were over 40. Neither passage establishes that clinical dementia often appears at ages 40–50; pathology and dementia are not interchangeable. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Di Domenico, F., Pupo, G., Mancuso, C., Barone, E., Paolini, F., Arena, A., Blarzino, C., Schmitt, F. A., Head, E., Butterfield, D. A., & Perluigi, M.
Affiliations
  • Department of Biochemical Sciences, Sapienza University of Rome, Italy
  • Sapienza University of Rome (IT)
  • Institute of Pharmacology, Catholic University School of Medicine, Rome, Italy
  • Instituto Nazionale Tumori Regina Elena (IT)
  • University of Kentucky (US)
Venue
Journal of Alzheimer’s Disease
Published
2015-02-19
Volume
44
Issue
4
Pages
1107-1120
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W1539907006
Cited by
75
References
89
Citations by year
2026: 5 · 2025: 8 · 2024: 9 · 2023: 3 · 2022: 8 · 2021: 7 · 2020: 11 · 2019: 4 · 2018: 11 · 2017: 5 · 2016: 2 · 2015: 2
FWCI
2.89
Type
journal article
Language
en
Open access
Locations
  • Journal of Alzheimer s Disease (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by-nc-nd)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • European Commission (2007–2013, FP7 2007-2013, 624341, FP7/2007)
  • National Institutes of Health (FP7/2007-2013, HHSN275200900011C,, AG-05119)
  • U.S. Public Health Service (#HHSN275200900011C)
  • National Institute on Aging (P50 AG 16573, P30AG028383, P01AG005119, P50AG016573, P30 AG28383, AG0 5119)
  • National Institute of Child Health and Human Development
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (HHSN275200900011C, R01HD064993, N01-HD-90011)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heme Oxygenase-1 and Carbon Monoxide
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
BACH1, Down syndrome
MeSH terms
Adolescent, Adult, Age Factors, Aged, Alzheimer Disease, Analysis of Variance, Animals, Brain, Child, Down Syndrome, Female, Gene Expression Regulation, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Oxidative Stress, Oxidoreductases Acting on CH-CH Group Donors, Immunoprecipitation, Basic-Leucine Zipper Transcription Factors, Mice, Heme Oxygenase-1, Fanconi Anemia Complementation Group Proteins, Ubiquitination, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review